IVVD - NASDAQ
Invivyd, Inc.
$1.10
-1.3%Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
At a Glance
Live SnapshotInvivyd, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Invivyd, Inc. Income Statement
IVVD • NASDAQ
| Invivyd, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
REVENUE | ||||||
53.4M | 25.4M | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | ||||||
(3.7M) | (1.6M) | (0.0) | (0.0) | (0.0) | (0.0) | |
49.7M | 23.8M | 0.0 | 0.0 | 0.0 | 0.0 | |
OPERATING INCOME | ||||||
(105.2M) | (200.6M) | (212.8M) | (248M) | (226.9M) | (112M) | |
(66.9M) | (63.4M) | (49.1M) | (47M) | (36.5M) | (0.0) | |
(38.3M) | (137.3M) | (158.7M) | (179.2M) | (182.9M) | (106.5M) | |
-55.6M | -176.9M | -212.8M | -248M | -226.9M | -112M | |
PRE-TAX INCOME | ||||||
(0.0) | (0.0) | (0.0) | (43.1M) | (0.0) | (0.0) | |
3.1M | 7M | 0.0 | -36.4M | 0.0 | 8K | |
(0.0) | (0.0) | (5M) | (21.8M) | (7.5M) | (5.5M) | |
3.1M | 7M | 14.1M | 6.7M | 118K | 13.7K | |
-52.5M | -169.9M | -198.6M | -241.3M | -226.8M | -112M | |
NET INCOME | ||||||
-52.5M | -169.9M | -198.6M | -241.3M | -226.8M | -112M |
SEC Filings
IVVD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 19, 2026 | May 19, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 09, 2026 | April 09, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 06, 2026 | May 19, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 05, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 08, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 23, 2025 | December 23, 2025 | 2025 | |
S-3/A S-3/A (Amended) N/A | December 19, 2025 | December 19, 2025 |
Related Guides
Continue your IVVD research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.